Cargando…
Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1
The inward rectifier family of potassium (Kir) channels is comprised of at least 16 family members exhibiting broad and often overlapping cellular, tissue, or organ distributions. The discovery of disease-causing mutations in humans and experiments on knockout mice has underscored the importance of...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254186/ https://www.ncbi.nlm.nih.gov/pubmed/22275899 http://dx.doi.org/10.3389/fphar.2011.00075 |
_version_ | 1782220810226761728 |
---|---|
author | Raphemot, Rene Lonergan, Daniel F. Nguyen, Thuy T. Utley, Thomas Lewis, L. Michelle Kadakia, Rishin Weaver, C. David Gogliotti, Rocco Hopkins, Corey Lindsley, Craig W. Denton, Jerod S. |
author_facet | Raphemot, Rene Lonergan, Daniel F. Nguyen, Thuy T. Utley, Thomas Lewis, L. Michelle Kadakia, Rishin Weaver, C. David Gogliotti, Rocco Hopkins, Corey Lindsley, Craig W. Denton, Jerod S. |
author_sort | Raphemot, Rene |
collection | PubMed |
description | The inward rectifier family of potassium (Kir) channels is comprised of at least 16 family members exhibiting broad and often overlapping cellular, tissue, or organ distributions. The discovery of disease-causing mutations in humans and experiments on knockout mice has underscored the importance of Kir channels in physiology and in some cases raised questions about their potential as drug targets. However, the paucity of potent and selective small-molecule modulators targeting specific family members has with few exceptions mired efforts to understand their physiology and assess their therapeutic potential. A growing body of evidence suggests that G protein-coupled inward rectifier K (GIRK) channels of the Kir3.X subfamily may represent novel targets for the treatment of atrial fibrillation. In an effort to expand the molecular pharmacology of GIRK, we performed a thallium (Tl(+)) flux-based high-throughput screen of a Kir1.1 inhibitor library for modulators of GIRK. One compound, termed VU573, exhibited 10-fold selectivity for GIRK over Kir1.1 (IC(50) = 1.9 and 19 μM, respectively) and was therefore selected for further study. In electrophysiological experiments performed on Xenopus laevis oocytes and mammalian cells, VU573 inhibited Kir3.1/3.2 (neuronal GIRK) and Kir3.1/3.4 (cardiac GIRK) channels with equal potency and preferentially inhibited GIRK, Kir2.3, and Kir7.1 over Kir1.1 and Kir2.1.Tl(+) flux assays were established for Kir2.3 and the M125R pore mutant of Kir7.1 to support medicinal chemistry efforts to develop more potent and selective analogs for these channels. The structure–activity relationships of VU573 revealed few analogs with improved potency, however two compounds retained most of their activity toward GIRK and Kir2.3 and lost activity toward Kir7.1. We anticipate that the VU573 series will be useful for exploring the physiology and structure–function relationships of these Kir channels. |
format | Online Article Text |
id | pubmed-3254186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Frontiers Research Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32541862012-01-24 Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1 Raphemot, Rene Lonergan, Daniel F. Nguyen, Thuy T. Utley, Thomas Lewis, L. Michelle Kadakia, Rishin Weaver, C. David Gogliotti, Rocco Hopkins, Corey Lindsley, Craig W. Denton, Jerod S. Front Pharmacol Pharmacology The inward rectifier family of potassium (Kir) channels is comprised of at least 16 family members exhibiting broad and often overlapping cellular, tissue, or organ distributions. The discovery of disease-causing mutations in humans and experiments on knockout mice has underscored the importance of Kir channels in physiology and in some cases raised questions about their potential as drug targets. However, the paucity of potent and selective small-molecule modulators targeting specific family members has with few exceptions mired efforts to understand their physiology and assess their therapeutic potential. A growing body of evidence suggests that G protein-coupled inward rectifier K (GIRK) channels of the Kir3.X subfamily may represent novel targets for the treatment of atrial fibrillation. In an effort to expand the molecular pharmacology of GIRK, we performed a thallium (Tl(+)) flux-based high-throughput screen of a Kir1.1 inhibitor library for modulators of GIRK. One compound, termed VU573, exhibited 10-fold selectivity for GIRK over Kir1.1 (IC(50) = 1.9 and 19 μM, respectively) and was therefore selected for further study. In electrophysiological experiments performed on Xenopus laevis oocytes and mammalian cells, VU573 inhibited Kir3.1/3.2 (neuronal GIRK) and Kir3.1/3.4 (cardiac GIRK) channels with equal potency and preferentially inhibited GIRK, Kir2.3, and Kir7.1 over Kir1.1 and Kir2.1.Tl(+) flux assays were established for Kir2.3 and the M125R pore mutant of Kir7.1 to support medicinal chemistry efforts to develop more potent and selective analogs for these channels. The structure–activity relationships of VU573 revealed few analogs with improved potency, however two compounds retained most of their activity toward GIRK and Kir2.3 and lost activity toward Kir7.1. We anticipate that the VU573 series will be useful for exploring the physiology and structure–function relationships of these Kir channels. Frontiers Research Foundation 2011-11-30 /pmc/articles/PMC3254186/ /pubmed/22275899 http://dx.doi.org/10.3389/fphar.2011.00075 Text en Copyright © 2011 Raphemot, Lonergan, Nguyen, Utley, Lewis, Kadakia, Weaver, Gogliotti, Hopkins, Lindsley and Denton. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits use, distribution, and reproduction in other forums, provided the original authors and source are credited. |
spellingShingle | Pharmacology Raphemot, Rene Lonergan, Daniel F. Nguyen, Thuy T. Utley, Thomas Lewis, L. Michelle Kadakia, Rishin Weaver, C. David Gogliotti, Rocco Hopkins, Corey Lindsley, Craig W. Denton, Jerod S. Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1 |
title | Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1 |
title_full | Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1 |
title_fullStr | Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1 |
title_full_unstemmed | Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1 |
title_short | Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1 |
title_sort | discovery, characterization, and structure–activity relationships of an inhibitor of inward rectifier potassium (kir) channels with preference for kir2.3, kir3.x, and kir7.1 |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254186/ https://www.ncbi.nlm.nih.gov/pubmed/22275899 http://dx.doi.org/10.3389/fphar.2011.00075 |
work_keys_str_mv | AT raphemotrene discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT lonergandanielf discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT nguyenthuyt discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT utleythomas discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT lewislmichelle discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT kadakiarishin discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT weavercdavid discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT gogliottirocco discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT hopkinscorey discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT lindsleycraigw discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 AT dentonjerods discoverycharacterizationandstructureactivityrelationshipsofaninhibitorofinwardrectifierpotassiumkirchannelswithpreferenceforkir23kir3xandkir71 |